<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00983645</url>
  </required_header>
  <id_info>
    <org_study_id>53271</org_study_id>
    <nct_id>NCT00983645</nct_id>
  </id_info>
  <brief_title>A Trial Comparing Prograf and Neoral Use in Kidney Transplant Recipients of Hispanic Ethnicity</brief_title>
  <official_title>A Prospective, Open-label, Randomized Trial Comparing Prograf and Neoral Use in Kidney Transplant Recipients of Hispanic Ethnicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loma Linda University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Loma Linda University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to compare outcomes in renal transplant recipients in the hispanic population
      based on their immunosuppressant regimens.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to include Hispanics who have undergone a renal transplant to determine the
      specific outcome after renal transplantation, assuming that ethnic groups require different
      immunosuppressant regimens. Trough levels in transplant recipients determine the dosing
      requirements for Tacrolimus and Cyclosproine. It has been recently found, however, that
      testing cyclosporine levels in the blood 2 hours after taking cyclosporine is more effective
      in dosing cyclosprine for renal transplant patients than trough levels. The specific study
      aims include comparing the cyclosporine monitoring in patients with trough and C2 levels, and
      adjusting immunosuppression based on C2 levels.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient funding
  </why_stopped>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rejection</measure>
    <time_frame>6 months post-transplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal Function</measure>
    <time_frame>6 months post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-transplant Diabetes Mellitus</measure>
    <time_frame>6 months post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid Levels</measure>
    <time_frame>6 months post-transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Renal Transplant Rejection</condition>
  <arm_group>
    <arm_group_label>Neoral</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neoral is a pill indicated for the prophylaxis of organ rejection in kidney transplants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prograf</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prograf is a medication used for the prophylaxis of rejection in allogeneic kidney transplants and may be used concomitantly with adrenal corticosteroids.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prograf</intervention_name>
    <description>Tacrolimus (Prograf) starting dose 0.05-0.15 mg/kg PO BID</description>
    <arm_group_label>Prograf</arm_group_label>
    <other_name>Tacrolimus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neoral</intervention_name>
    <description>Cyclosporine (Neoral) starting dose 3mg/kg PO BID</description>
    <arm_group_label>Neoral</arm_group_label>
    <other_name>Cyclosporine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cadaveric or Living Donors

          -  18 years old or greater

          -  Primary renal transplants

          -  Hispanic ethnicity

        Exclusion Criteria:

          -  Prior renal transplant

          -  Multi-organ transplant

          -  Recipient with history of Diabetes Mellitus

          -  PRA &gt; 20%

          -  Cold Ischemia Time &gt; 24 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro Baron, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loma Linda University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Neylan JF. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group. Transplantation. 1998 Feb 27;65(4):515-23.</citation>
    <PMID>9500626</PMID>
  </reference>
  <reference>
    <citation>First MR, Gerber DA, Hariharan S, Kaufman DB, Shapiro R. Posttransplant diabetes mellitus in kidney allograft recipients: incidence, risk factors, and management. Transplantation. 2002 Feb 15;73(3):379-86.</citation>
    <PMID>11884934</PMID>
  </reference>
  <reference>
    <citation>Jindal RM, Hjelmesaeth J. Impact and management of posttransplant diabetes mellitus. Transplantation. 2000 Dec 15;70(11 Suppl):SS58-63. Review.</citation>
    <PMID>11152233</PMID>
  </reference>
  <reference>
    <citation>Knoll GA, Bell RC. Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials. BMJ. 1999 Apr 24;318(7191):1104-7.</citation>
    <PMID>10213717</PMID>
  </reference>
  <reference>
    <citation>Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation. 1997 Apr 15;63(7):977-83.</citation>
    <PMID>9112351</PMID>
  </reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2009</study_first_submitted>
  <study_first_submitted_qc>September 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2009</study_first_posted>
  <results_first_submitted>September 17, 2015</results_first_submitted>
  <results_first_submitted_qc>September 17, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 20, 2015</results_first_posted>
  <last_update_submitted>April 28, 2016</last_update_submitted>
  <last_update_submitted_qc>April 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney Transplantation</keyword>
  <keyword>Immunosuppression</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Neoral</title>
          <description>Neoral is a pill indicated for the prophylaxis of organ rejection in kidney transplants
Neoral: Cyclosporine (Neoral) starting dose 3mg/kg PO BID</description>
        </group>
        <group group_id="P2">
          <title>Prograf</title>
          <description>Prograf is a medication used for the prophylaxis of rejection in allogeneic kidney transplants and may be used concomitantly with adrenal corticosteroids.
Prograf: Tacrolimus (Prograf) starting dose 0.05-0.15 mg/kg PO BID</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Neoral</title>
          <description>Neoral is a pill indicated for the prophylaxis of organ rejection in kidney transplants
Neoral: Cyclosporine (Neoral) starting dose 3mg/kg PO BID</description>
        </group>
        <group group_id="B2">
          <title>Prograf</title>
          <description>Prograf is a medication used for the prophylaxis of rejection in allogeneic kidney transplants and may be used concomitantly with adrenal corticosteroids.
Prograf: Tacrolimus (Prograf) starting dose 0.05-0.15 mg/kg PO BID</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.875" lower_limit="18" upper_limit="53"/>
                    <measurement group_id="B2" value="42.14" lower_limit="29" upper_limit="56"/>
                    <measurement group_id="B3" value="35.6" lower_limit="18" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rejection</title>
        <time_frame>6 months post-transplant</time_frame>
        <population>Data cannot be located for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Neoral</title>
            <description>Neoral is a pill indicated for the prophylaxis of organ rejection in kidney transplants
Neoral: Cyclosporine (Neoral) starting dose 3mg/kg PO BID</description>
          </group>
          <group group_id="O2">
            <title>Prograf</title>
            <description>Prograf is a medication used for the prophylaxis of rejection in allogeneic kidney transplants and may be used concomitantly with adrenal corticosteroids.
Prograf: Tacrolimus (Prograf) starting dose 0.05-0.15 mg/kg PO BID</description>
          </group>
        </group_list>
        <measure>
          <title>Rejection</title>
          <population>Data cannot be located for analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Function</title>
        <time_frame>6 months post-transplant</time_frame>
        <population>Data cannot be located for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Neoral</title>
            <description>Neoral is a pill indicated for the prophylaxis of organ rejection in kidney transplants
Neoral: Cyclosporine (Neoral) starting dose 3mg/kg PO BID</description>
          </group>
          <group group_id="O2">
            <title>Prograf</title>
            <description>Prograf is a medication used for the prophylaxis of rejection in allogeneic kidney transplants and may be used concomitantly with adrenal corticosteroids.
Prograf: Tacrolimus (Prograf) starting dose 0.05-0.15 mg/kg PO BID</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Function</title>
          <population>Data cannot be located for analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-transplant Diabetes Mellitus</title>
        <time_frame>6 months post-transplant</time_frame>
        <population>Data cannot be located for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Neoral</title>
            <description>Neoral is a pill indicated for the prophylaxis of organ rejection in kidney transplants
Neoral: Cyclosporine (Neoral) starting dose 3mg/kg PO BID</description>
          </group>
          <group group_id="O2">
            <title>Prograf</title>
            <description>Prograf is a medication used for the prophylaxis of rejection in allogeneic kidney transplants and may be used concomitantly with adrenal corticosteroids.
Prograf: Tacrolimus (Prograf) starting dose 0.05-0.15 mg/kg PO BID</description>
          </group>
        </group_list>
        <measure>
          <title>Post-transplant Diabetes Mellitus</title>
          <population>Data cannot be located for analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lipid Levels</title>
        <time_frame>6 months post-transplant</time_frame>
        <population>Data cannot be located for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Neoral</title>
            <description>Neoral is a pill indicated for the prophylaxis of organ rejection in kidney transplants
Neoral: Cyclosporine (Neoral) starting dose 3mg/kg PO BID</description>
          </group>
          <group group_id="O2">
            <title>Prograf</title>
            <description>Prograf is a medication used for the prophylaxis of rejection in allogeneic kidney transplants and may be used concomitantly with adrenal corticosteroids.
Prograf: Tacrolimus (Prograf) starting dose 0.05-0.15 mg/kg PO BID</description>
          </group>
        </group_list>
        <measure>
          <title>Lipid Levels</title>
          <population>Data cannot be located for analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Standard practice</desc>
      <group_list>
        <group group_id="E1">
          <title>Neoral</title>
          <description>Neoral is a pill indicated for the prophylaxis of organ rejection in kidney transplants
Neoral: Cyclosporine (Neoral) starting dose 3mg/kg PO BID</description>
        </group>
        <group group_id="E2">
          <title>Prograf</title>
          <description>Prograf is a medication used for the prophylaxis of rejection in allogeneic kidney transplants and may be used concomitantly with adrenal corticosteroids.
Prograf: Tacrolimus (Prograf) starting dose 0.05-0.15 mg/kg PO BID</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>A limitation to this study is early termination leading to a small number of subjects.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Pedro Baron</name_or_title>
      <organization>Loma Linda University Medical Center Transplantation Institute</organization>
      <phone>909-558-3636 ext 36792</phone>
      <email>pbaron@llu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

